These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 10408570)
1. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Verrotti A; Basciani F; Morresi S; de Martino M; Morgese G; Chiarelli F Neurology; 1999 Jul; 53(1):230-2. PubMed ID: 10408570 [TBL] [Abstract][Full Text] [Related]
2. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. Verrotti A; Basciani F; De Simone M; Trotta D; Morgese G; Chiarelli F J Child Neurol; 2002 Apr; 17(4):265-8. PubMed ID: 12088081 [TBL] [Abstract][Full Text] [Related]
3. States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. Hamed SA; Fida NM; Hamed EA Eur J Paediatr Neurol; 2009 May; 13(3):261-8. PubMed ID: 18586538 [TBL] [Abstract][Full Text] [Related]
4. The role of ghrelin in weight gain and growth in epileptic children using valproate. Gungor S; Yücel G; Akinci A; Tabel Y; Ozerol IH; Yologlu S J Child Neurol; 2007 Dec; 22(12):1384-8. PubMed ID: 18174556 [TBL] [Abstract][Full Text] [Related]
5. The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children. Çiçek NP; Kamaşak T; Serin M; Okten A; Alver A; Cansu A Seizure; 2018 May; 58():90-95. PubMed ID: 29679911 [TBL] [Abstract][Full Text] [Related]
6. Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate. Aydin K; Serdaroglu A; Okuyaz C; Bideci A; Gucuyener K J Child Neurol; 2005 Oct; 20(10):848-51. PubMed ID: 16417885 [TBL] [Abstract][Full Text] [Related]
7. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Luef G; Abraham I; Hoppichler F; Trinka E; Unterberger I; Bauer G; Lechleitner M Metabolism; 2002 Oct; 51(10):1274-8. PubMed ID: 12370846 [TBL] [Abstract][Full Text] [Related]
8. Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy. Kanemura H; Sano F; Maeda Y; Sugita K; Aihara M Seizure; 2012 Sep; 21(7):496-500. PubMed ID: 22694920 [TBL] [Abstract][Full Text] [Related]
9. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Verrotti A; D'Egidio C; Mohn A; Coppola G; Chiarelli F Obes Rev; 2011 May; 12(5):e32-43. PubMed ID: 20880119 [TBL] [Abstract][Full Text] [Related]
10. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Grosso S; Mostardini R; Piccini B; Balestri P Ann Pharmacother; 2009 Jan; 43(1):45-50. PubMed ID: 19066323 [TBL] [Abstract][Full Text] [Related]
11. Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study. Sidhu HS; Srinivas R; Sadhotra A Seizure; 2017 May; 48():15-21. PubMed ID: 28365440 [TBL] [Abstract][Full Text] [Related]
12. Valproate, weight gain and carbohydrate craving: a gender study. El-Khatib F; Rauchenzauner M; Lechleitner M; Hoppichler F; Naser A; Waldmann M; Trinka E; Unterberger I; Bauer G; Luef GJ Seizure; 2007 Apr; 16(3):226-32. PubMed ID: 17210261 [TBL] [Abstract][Full Text] [Related]
13. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Greco R; Latini G; Chiarelli F; Iannetti P; Verrotti A Neurology; 2005 Dec; 65(11):1808-9. PubMed ID: 16344528 [TBL] [Abstract][Full Text] [Related]
14. Metabolic and endocrine effects of valproic acid chronic treatment. Belcastro V; D'Egidio C; Striano P; Verrotti A Epilepsy Res; 2013 Nov; 107(1-2):1-8. PubMed ID: 24076030 [TBL] [Abstract][Full Text] [Related]
15. Valproate-associated reproductive hormone abnormalities: do bipolar men have the same risk as epileptic men? Aldemir E; Akdeniz F; Altay AB; Arıcı Ş; Umul M; Aydın HH; Çelebisoy M; Vahip S Turk Psikiyatri Derg; 2012; 23(4):223-7. PubMed ID: 23225122 [TBL] [Abstract][Full Text] [Related]
16. C-peptide and insulin, but not C19-steroids, support the predictive value of body mass index on leptin in serum of premenopausal women. Geisthövel F; Meysing A; Brabant G Hum Reprod; 1998 Mar; 13(3):547-53. PubMed ID: 9572408 [TBL] [Abstract][Full Text] [Related]
17. Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy. Grosso S; Luisi S; Mostardini R; Matera M; Barlocco EG; Casarosa E; Balestri P; Petraglia F Neuroendocrinology; 2011; 93(3):159-64. PubMed ID: 20980729 [TBL] [Abstract][Full Text] [Related]
18. Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate. Tokgoz H; Aydin K; Oran B; Kiyici A Childs Nerv Syst; 2012 Jul; 28(7):1049-53. PubMed ID: 22645062 [TBL] [Abstract][Full Text] [Related]
19. Adiponectin and visfatin concentrations in children treated with valproic acid. Rauchenzauner M; Haberlandt E; Scholl-Bürgi S; Ernst B; Hoppichler F; Karall D; Ebenbichler CF; Rostasy K; Luef G Epilepsia; 2008 Feb; 49(2):353-7. PubMed ID: 18070089 [TBL] [Abstract][Full Text] [Related]
20. Serum insulin, cortisol, leptin, neuropeptide Y, galanin and ghrelin levels in epileptic children receiving valproate. Cansu A; Serdaroglu A; Camurdan O; Hırfanoğlu T; Cinaz P Horm Res Paediatr; 2011; 76(1):65-71. PubMed ID: 21659721 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]